Groundwork laid for lifesaving GBS vaccine trials in africa
NCT ID NCT06833957
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study prepares medical sites in Kenya, Malawi, Mozambique, and Uganda for future trials of a vaccine against Group B Streptococcus (GBS), a leading cause of serious infections in newborns. Researchers will track pregnancy and infant health data and monitor GBS cases in babies under 90 days old. The goal is to build a network that can test and monitor the safety of GBS vaccines, ultimately preventing newborn deaths.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GROUP B STREPTOCOCCUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Geral De Mavalane
RECRUITINGMaputo, Cidade de Maputo, 1100, Mozambique
-
Kawempe National Referral Hospital
RECRUITINGKampala, Kampala, P. O Box 3253, Uganda
-
Komamboga Health Centre III
RECRUITINGKampala, Komamboga, 4126, Uganda
-
Lirangwe Health Centre
RECRUITINGBlantyre, Blantyre District, Malawi
-
Malindi Sub County Hospital in Malindi
RECRUITINGMalindi, Kilifi County, 80200, Kenya
-
Manhiça District Hospital
RECRUITINGManhiça, Manhiça, Mozambique
-
Mariakani Sub-County Hospital
RECRUITINGMariakani, Coast, 80113, Kenya
-
Ndirande Health Centre
RECRUITINGBlantyre, Blantyre, Malawi
-
Queen Elizabeth Central Hospital
RECRUITINGBlantyre, Blantyre District, Box 95, Malawi
-
Rabai Sub County Hospital
RECRUITINGRabai, Kilifi County, 80114, Kenya
More trials for these conditions
Other studies related to the condition(s) this trial covers.